ATE299028T1 - Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin - Google Patents

Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin

Info

Publication number
ATE299028T1
ATE299028T1 AT01974510T AT01974510T ATE299028T1 AT E299028 T1 ATE299028 T1 AT E299028T1 AT 01974510 T AT01974510 T AT 01974510T AT 01974510 T AT01974510 T AT 01974510T AT E299028 T1 ATE299028 T1 AT E299028T1
Authority
AT
Austria
Prior art keywords
aplidine
carnitine
acetylcarnitine
treatment
combination
Prior art date
Application number
AT01974510T
Other languages
English (en)
Inventor
Lazaro Luis Lopez
Sousa Jose Maria Fernandez
Jean-Pierre Armand
Eric Raymond
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0025044A external-priority patent/GB0025044D0/en
Priority claimed from GB0025209A external-priority patent/GB0025209D0/en
Priority claimed from PCT/GB2000/004349 external-priority patent/WO2001035974A2/en
Priority claimed from GB0107373A external-priority patent/GB0107373D0/en
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Priority claimed from PCT/GB2001/004555 external-priority patent/WO2002030441A2/en
Application granted granted Critical
Publication of ATE299028T1 publication Critical patent/ATE299028T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
AT01974510T 2000-10-12 2001-10-12 Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin ATE299028T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0025044A GB0025044D0 (en) 2000-10-12 2000-10-12 Toxicity protection
GB0025209A GB0025209D0 (en) 2000-10-13 2000-10-13 Treatment of cancers
PCT/GB2000/004349 WO2001035974A2 (en) 1999-11-15 2000-11-15 Aplidine treatment of cancers
GB0107373A GB0107373D0 (en) 2001-03-23 2001-03-23 Aplidine
PCT/GB2001/004555 WO2002030441A2 (en) 2000-10-12 2001-10-12 Treatment of cancers by aplidine in conjunction with a myoprotector

Publications (1)

Publication Number Publication Date
ATE299028T1 true ATE299028T1 (de) 2005-07-15

Family

ID=27255931

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01974510T ATE299028T1 (de) 2000-10-12 2001-10-12 Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin

Country Status (14)

Country Link
US (1) US7507766B2 (de)
JP (1) JP2010031043A (de)
KR (1) KR20030038812A (de)
CN (1) CN1479622A (de)
AT (1) ATE299028T1 (de)
BR (1) BR0114604A (de)
CZ (1) CZ2003993A3 (de)
ES (1) ES2243555T3 (de)
HK (1) HK1054191A1 (de)
IL (1) IL155273A0 (de)
NO (1) NO20031673L (de)
NZ (1) NZ525196A (de)
PL (1) PL361179A1 (de)
RU (1) RU2003113210A (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302498B6 (cs) * 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
EP1620117A4 (de) * 2003-03-12 2009-07-29 Pharma Mar Sa Verbesserte antitumorale behandlungen
EP1942944A2 (de) * 2005-10-31 2008-07-16 Genentech, Inc. Makrozyklische depsipeptid-antikörper-wirkstoff-konjugate und entsprechende verfahren
WO2007101235A2 (en) * 2006-02-28 2007-09-07 Pharma Mar, S.A. Improved antitumoral treatments
AU2008313627A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
CA2717409A1 (en) * 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5861439A (en) 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
ES2151277T3 (es) 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
EP0918693B1 (de) 1996-07-03 2001-11-07 C G Paxton Limited Behälter
DE69735583T2 (de) 1996-10-24 2007-04-05 The Board Of Trustees Of The University Of Illinois, Urbana Semisynthetisches verfahren zur herstellung von didemninanalogen
US6380156B1 (en) 1996-10-24 2002-04-30 The Board Of Trustees Of The University Of Illnois Total synthesis of the amino hip analogue of didemnin A
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
AU781897B2 (en) 1999-05-25 2005-06-23 Point Therapeutics, Inc. Anti-tumor comprising boroproline compounds
CZ302498B6 (cs) 1999-11-15 2011-06-15 Pharma Mar, S. A. Farmaceutický prípravek obsahující aplidin pro lécení rakovinových onemocnení
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
AU1305302A (en) 2000-10-05 2002-04-15 Immunex Corp Nectin polypeptides, polynucleotides, methods of making and use thereof
MXPA03003230A (es) 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
DE60229414D1 (de) 2001-10-19 2008-11-27 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
EP1620117A4 (de) 2003-03-12 2009-07-29 Pharma Mar Sa Verbesserte antitumorale behandlungen

Also Published As

Publication number Publication date
IL155273A0 (en) 2003-11-23
US20040010043A1 (en) 2004-01-15
CN1479622A (zh) 2004-03-03
JP2010031043A (ja) 2010-02-12
ES2243555T3 (es) 2005-12-01
US7507766B2 (en) 2009-03-24
PL361179A1 (en) 2004-09-20
RU2003113210A (ru) 2004-11-27
CZ2003993A3 (cs) 2004-02-18
HK1054191A1 (zh) 2003-11-21
BR0114604A (pt) 2003-10-14
KR20030038812A (ko) 2003-05-16
NO20031673L (no) 2003-06-12
NO20031673D0 (no) 2003-04-11
NZ525196A (en) 2004-09-24

Similar Documents

Publication Publication Date Title
ES543862A0 (es) Procedimiento para apreciar variaciones en el tiempo de caracteristicas somaticas de personas sometidas a tratamiento deadelgazamiento, cicatrizacion y otros.
EA200700684A1 (ru) Полиаминные композиции
ATE173155T1 (de) Mittel zur künstlichen bräunung mit verbesserter stabilität
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
EA200500986A1 (ru) Применение капсаициноидов
DE60315964D1 (de) Verbesserung der herstellung von endogenen gonadotropin
MX9400434A (es) Potenciamiento de temozolomida en celulas de tumores humanos.
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
ATE299028T1 (de) Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin
IL138290A0 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DK0994704T3 (da) Anvendelse af GABA-analoger såsom gabapentin i fremstillingen af et medikament til behandling af inflammatoriske sygdomme
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
DE60111858D1 (de) BEHANDLUNG VON KREBSERKRANKUNGEN mit APLIDIN IN KOMBINATION MIT CARNITIN ODER ACETYLCARNITIN
PA8506201A1 (es) Quimioterapia de combinacion (combination chemotherapy)
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
DK0572549T3 (da) Behandling af ikke-småcellet lungecarcinom
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
MXPA04000418A (es) Tratamiento de dolor cronico con 3-heterocicloxi- y -cicloalquiloxi-3-fenilpropanaminas.
DK1137420T3 (da) Anvendelse af en kombination af et purin og en nitrogenmonooxiddonor til forebyggelse eller behandling af sexuel dysfunktion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties